Hydroxycarbamid Devatis (Hydroxycarbamide)

Hydroxycarbamide blocks ribonucleotide reductase, the enzyme responsible for converting ribonucleotides into deoxyribonucleotides. By limiting the supply of DNA building blocks, it suppresses DNA synthesis and cell division, especially in rapidly dividing malignant or dysregulated blood cells, and can increase fetal hemoglobin production in sickle cell disease.

The exact dose of Hydroxycarbamid Devatis is individualized by the prescribing clinician. Dosage depends on the specific indication, patient weight, renal and hepatic function, baseline blood counts, and response to therapy. Physicians adjust the regimen based on laboratory monitoring and clinical judgment rather than a fixed standard.

Safety data for hydroxycarbamide in pregnancy and lactation are limited, and the drug is classified as having an unknown pregnancy category. It should only be used when the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Hydroxycarbamid Devatis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details and any required import documentation.

Hydroxycarbamide belongs to the antimetabolite class and is often compared with other cytoreductive agents such as interferon‑alpha or busulfan. Compared with interferon, hydroxycarbamide is oral, generally easier to administer, and has a different side‑effect profile, while interferon may be preferred for patients who cannot tolerate myelosuppression. Choice depends on disease specifics and patient tolerance.

Hydroxycarbamid Devatis should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, heat and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Hydroxycarbamid Devatis is taken orally. The tablet (or oral formulation) should be swallowed whole with a glass of water, preferably at the same time each day to maintain consistent blood levels. Patients should follow the prescribing clinician’s instructions regarding food intake, as absorption may be affected by meals.

The most serious adverse events include severe bone‑marrow suppression leading to pancytopenia, which can cause life‑threatening infections or bleeding, and acute pulmonary toxicity such as interstitial pneumonitis. Renal failure and rare severe skin reactions (e.g., Stevens‑Johnson syndrome) also require immediate medical attention.

Hydroxycarbamid Devatis is contraindicated in patients with known hypersensitivity to hydroxycarbamide or any component of the formulation. It should be avoided in individuals with severe active infections, uncontrolled liver disease, or pre‑existing severe bone‑marrow failure. Pregnant or breastfeeding women should only use it when clearly indicated and after specialist consultation.